{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:50:07Z","timestamp":1775062207630,"version":"3.50.1"},"reference-count":24,"publisher":"Central Research Institute for Epidemiology","issue":"3","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["virusjour.crie.ru"],"crossmark-restriction":false},"short-container-title":["Problems of Virology"],"abstract":"<jats:p>Introduction. Intranasal vaccination using live vector vaccines based on non-pathogenic or slightly pathogenic viruses is the one of the most convenient, safe and effective ways to prevent respiratory infections, including COVID-19. Sendai virus is the best suited for this purpose, since it is respiratory virus and is capable of limited replication in human bronchial epithelial cells without causing disease.\r\nThe aim of the work is to design and study the vaccine properties of recombinant Sendai virus, Moscow strain, expressing secreted receptor-binding domain of SARS-CoV-2 Delta strain S protein (RBDdelta) during a single intranasal immunization.\r\nMaterials and methods. Recombinant Sendai virus carrying insertion of RBDdelta transgene between P and M genes was constructed using reverse genetics and synthetic biology methods. Expression of RBDdelta was analyzed by Western blot. Vaccine properties were studied in two models: Syrian hamsters and BALB\/c mice. Immunogenicity was evaluated by ELISA and virus-neutralization assays. Protectiveness was assessed by quantitation of SARS-CoV-2 RNA in RT-PCR and histological analysis of the lungs.\r\nResults. Based on Sendai virus Moscow strain, a recombinant Sen-RBDdelta(M) was constructed that expressed a secreted RBDdelta immunologically identical to natural SARS-CoV-2 protein. A single intranasal administration of Sen-RBDdelta(M) to hamsters and mice significantly, by 15 and 107 times, respectively, reduced replicative activity of SARS-CoV-2 in lungs of animals, preventing the development of pneumonia. An effective induction of virus-neutralizing antibodies has also been demonstrated in mice.\r\nConclusion. Sen-RBDdelta(M) is a promising vaccine construct against SARS-CoV-2 infection and has a protective properties even after a single intranasal introduction.<\/jats:p>","DOI":"10.36233\/0507-4088-172","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T09:59:29Z","timestamp":1688637569000},"page":"215-227","update-policy":"https:\/\/doi.org\/10.36233\/0372-9311-crossmark","source":"Crossref","is-referenced-by-count":3,"title":["Intranasal vaccine against COVID-19 based on a recombinant variant of the Sendai virus (Paramyxoviridae: &lt;i&gt;Respirovirus&lt;\/i&gt;) strain Moscow"],"prefix":"10.36233","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8251-7040","authenticated-orcid":false,"given":"Gleb A.","family":"Kudrov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5818-4402","authenticated-orcid":false,"given":"Sergei S.","family":"Zainutdinov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7712-3699","authenticated-orcid":false,"given":"Antonina A.","family":"Grazhdantseva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1201-8307","authenticated-orcid":false,"given":"Andrey V.","family":"Shipovalov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8362-0314","authenticated-orcid":false,"given":"Galina F.","family":"Sivolobova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7767-0537","authenticated-orcid":false,"given":"Anastasiya V.","family":"Semenova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6974-0686","authenticated-orcid":false,"given":"Iuliia A.","family":"Merkuleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8023-4453","authenticated-orcid":false,"given":"Dmitry N.","family":"Shcherbakov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6746-8092","authenticated-orcid":false,"given":"Oleg S.","family":"Taranov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0450-5212","authenticated-orcid":false,"given":"Anna V.","family":"Zaykovskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6850-338X","authenticated-orcid":false,"given":"Irina S.","family":"Shulgina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3340-8750","authenticated-orcid":false,"given":"Oleg V.","family":"Pyankov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2420-0483","authenticated-orcid":false,"given":"Galina V.","family":"Kochneva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22004","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"ref1","unstructured":"WHO. COVID-19 vaccine tracker and landscape. Available at: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Wang N., Shang J., Jiang S., Du L. Subunit vaccines against emerging pathogenic human coronaviruses. Front. Microbiol. 2020; 11: 298. https:\/\/doi.org\/10.3389\/fmicb.2020.00298","DOI":"10.3389\/fmicb.2020.00298"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Lund F.E., Randall T.D. Scent of a vaccine. Science. 2021; 373(6553): 397\u20139. https:\/\/doi.org\/10.1126\/science.abg9857","DOI":"10.1126\/science.abg9857"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Zaynutdinov S.S., Sivolobova G.F., Loktev V.B., Kochneva G.V. Mucosal immunity and vaccines against viral infections. Voprosy virusologii. 2021; 66(6): 399\u2013408. https:\/\/doi.org\/10.36233\/0507-4088-82 (in Russian)","DOI":"10.36233\/0507-4088-82"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Zaychuk T.A., Nechipurenko Yu.D., Adzhubey A.A., Onikienko S.B., Chereshnev V.A., Zaynutdinov S.S., et al. The challenges of vaccine development against betacoronaviruses: antibody dependent enhancementand sendai virus as a possible vaccine vector. Molekulyarnaya biologiya. 2020; 54(6): 922\u201338. https:\/\/doi.org\/10.31857\/S0026898420060154 https:\/\/www.elibrary.ru\/cfddrc (in Russian)","DOI":"10.1134\/S0026893320060151"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Cantell K., Hirvonen S., Kauppinen H.L., Myllyl\u00e4 G. Production of interferon in human leukocytes from normal donors with the use of Sendai virus. Methods Enzymol. 1981; 78(Pt. A): 29\u201338. https:\/\/doi.org\/10.1016\/0076-6879(81)78094-7","DOI":"10.1016\/0076-6879(81)78094-7"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Nyman T.A., T\u00f6l\u00f6 H., Parkkinen J., Kalkkinen N. Identification of nine interferon-alpha subtypes produced by Sendai virus-induced human peripheral blood leucocytes. Biochem. J. 1998; 329(Pt. 2): 295\u2013302. https:\/\/doi.org\/10.1042\/bj3290295","DOI":"10.1042\/bj3290295"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Matsumoto Y., Ohta K., Kolakofsky D., Nishio M. The control of paramyxovirus genome hexamer length and mRNA editing. RNA. 2018; 24(4): 461\u20137. https:\/\/doi.org\/10.1261\/rna.065243.117","DOI":"10.1261\/rna.065243.117"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Morimoto S., Saeki K., Takeshita M., Hirano K., Shirakawa M., Yamada Y., et al. Intranasal Sendai virus-based SARS-CoV-2 vaccine using a mouse model. Genes Cells. 2023; 28(1): 29\u201341. https:\/\/doi.org\/10.1111\/gtc.12992","DOI":"10.1111\/gtc.12992"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Scaggs Huang F., Bernstein D.I., Slobod K.S., Portner A., Takimoto T., Russell C.J., et al. Safety and immunogenicity of an intranasal Sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults. Hum. Vaccin. Immunother. 2021; 17(2): 554\u20139. https:\/\/doi.org\/10.1080\/21645515.2020.1779517","DOI":"10.1080\/21645515.2020.1779517"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Russell C.J., Hurwitz J.L. Sendai virus-vectored vaccines that express envelope glycoproteins of respiratory viruses. Viruses. 2021; 13(6): 1023. https:\/\/doi.org\/10.3390\/v13061023","DOI":"10.3390\/v13061023"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Zainutdinov S.S., Tikunov A.Y., Matveeva O.V., Netesov S.V., Kochneva G.V. Complete genome sequence of the oncolytic Sendai virus strain Moscow. Genome Announc. 2016; 4(4): e00818\u201316. https:\/\/doi.org\/10.1128\/genomea.00818-16","DOI":"10.1128\/genomeA.00818-16"},{"key":"ref13","unstructured":"Kochneva G.V., Grazhdantseva A.A., Sivolobova G.F., Zaynutdinov S.S. A set of recombinant plasmid DNA for obtaining recombinant Sendai viruses strain Moscow (variants). Patent RF \u2116 2787724; 2023. (in Russian)"},{"key":"ref14","unstructured":"Addgene. T7opt in pCAGGS. Available at: https:\/\/www.addgene.org\/65974"},{"key":"ref15","unstructured":"NovoPro. pCDH-EF1a-MCS-IRES-zeo vector map and sequence. Available at: https:\/\/www.novoprolabs.com\/vector\/Vgm4tkma"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Merkuleva I.A., Shcherbakov D.N., Borgoyakova M.B., Shanshin D.V., Rudometov A.P., Karpenko L.I., et al. Comparative immunogenicity of the recombinant receptor-binding domain of protein S SARS-CoV-2 obtained in prokaryotic and mammalian expression systems. Vaccines (Basel). 2022; 10(1): 96. https:\/\/doi.org\/10.3390\/vaccines10010096","DOI":"10.3390\/vaccines10010096"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Tatsumoto N., Miyauchi T., Arditi M., Yamashita M. Quantification of infectious Sendai virus using plaque assay. Bio Protoc. 2018; 8(21): e3068. https:\/\/doi.org\/10.21769\/bioprotoc.3068","DOI":"10.21769\/BioProtoc.3068"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Shipovalov A.V., Kudrov G.A., Tomilov A.A., Bodnev S.A., Boldyrev N.D., Ovchinnikova A.S., et al. Pathogenicity of the SARS-COV-2 virus variants of concern for the Syrian golden hamster. Problemy osobo opasnykh infektsiy. 2022; (3): 164\u20139. https:\/\/doi.org\/10.21055\/0370-1069-2022-3-164-169 https:\/\/www.elibrary.ru\/mirlbr (in Russian)","DOI":"10.21055\/0370-1069-2022-3-164-169"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Shipovalov A.V., Kudrov G.A., Tomilov A.A., Bodnev S.A., Boldyrev N.D., Ovchinnikova A.S., et al. Susceptibility to SARS-CoV-2 virus variants of concern in mouse models. Problemy osobo opasnykh infektsiy. 2022; (1): 148\u201355. https:\/\/doi.org\/10.21055\/0370-1069-2022-1-148-155 https:\/\/www.elibrary.ru\/vgamvf (in Russian)","DOI":"10.21055\/0370-1069-2022-1-148-155"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Matveeva O.V., Kochneva G.V., Netesov S.V., Onikienko S.B., Chumakov P.M. Mechanisms of oncolysis by paramyxovirus Sendai. Acta Naturae. 2015; 7(2): 6\u201316.","DOI":"10.32607\/20758251-2015-7-2-6-16"},{"key":"ref21","unstructured":"Merkul\u2019eva Yu.A., Shcherbakov D.N., Belen\u2019kaya S.V., Isaeva A.A., Nesmeyanova V.S., Shan\u2019shin D.V., et al. Integrative plasmid vector pVEAL2-S-RBD providing expression and secretion of the recombinant receptor-binding domain (RBD) of the SARS-CoV-2 coronavirus in mammalian cells, recombinant strain of the CHO-R1-RBD cell line and recombinant SARS-CoV-2 RBD protein produced by the specified strain of the cell line CHO-K1-RBD. Patent RF \u2116 2752858; 2021."},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Merkuleva I.A., Shcherbakov D.N., Borgoyakova M.B., Isaeva A.A., Nesmeyanova V.S., Volkova N.V., et al. Are hamsters a suitable model for evaluating the immunogenicity of RBD-based anti-COVID-19 subunit vaccines? Viruses. 2022; 14(5): 1060. https:\/\/doi.org\/10.3390\/v14051060","DOI":"10.3390\/v14051060"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Ilinykh P.A., Periasamy S., Huang K., Kuzmina N.A., Ramanathan P., Meyer M.N., et al. A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2. NPJ Vaccines. 2022; 7(1): 47. https:\/\/doi.org\/10.1038\/s41541-022-00471-3","DOI":"10.1038\/s41541-022-00471-3"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Castro J.T., Fumagalli M.J., Hojo-Souza N.S., Azevedo P., Salazar N., Rattis B., et al. Neutralizing antibody \u2013 independent immunity to SARS-CoV-2 in hamsters and hACE-2 transgenic mice immunized with a RBD\/nucleocapsid fusion protein. BioRxiv. 2021. Preprint. https:\/\/doi.org\/10.1101\/2021.09.16.460663","DOI":"10.1101\/2021.09.16.460663"}],"container-title":["Problems of Virology"],"original-title":[],"link":[{"URL":"https:\/\/virusjour.crie.ru\/jour\/article\/viewFile\/7167\/778","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/virusjour.crie.ru\/jour\/article\/viewFile\/7167\/778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T09:59:46Z","timestamp":1688637586000},"score":1,"resource":{"primary":{"URL":"https:\/\/virusjour.crie.ru\/jour\/article\/view\/7167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,7,6]]}},"URL":"https:\/\/doi.org\/10.36233\/0507-4088-172","relation":{},"ISSN":["2411-2097","0507-4088"],"issn-type":[{"value":"2411-2097","type":"electronic"},{"value":"0507-4088","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,6]]}}}